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ABSTRACT 
Objectives: 
Despite advances in novel drug development for patients with advanced non-
small cell lung cancer (NSCLC), there are still only a limited number of 
approved treatments. We therefore evaluated the clinical outcomes of patients 
with advanced NSCLC referred to a dedicated phase I clinical trials unit, 
assessed baseline clinical factors associated with successful enrollment onto 
phase I trials and validated the Royal Marsden Hospital (RMH) prognostic 
score in patients with advanced NSCLC. 
Material and methods: 
We conducted a retrospective study involving patients with advanced NSCLC 
referred to the Drug Development Unit at the RMH between January 2005 
and December 2013. 
Results: 
257 patients with advanced NSCLC were referred for consideration of phase I 
trials, of which only 89 (35%) patients successfully commenced phase I trials. 
The commonest reasons for not entering study included poor ECOG 
performance status and rapid disease progression. A multivariate analysis 
identified that ECOG performance status (0-1) and RMH prognostic score (0-
1) were associated with successful enrollment onto phase I trials (p<0.001); 
this validated the use of the RMH prognostic score in patients with advanced 
NSCLC. Single agent therapies included novel agents against the 
phosphatidylinositol-3 kinase pathway, insulin growth factor-1 receptor and 
pan-HER family tyrosine kinases. These trial therapies were well tolerated 
and mainly associated with grade 1-2 adverse events, with a minority 
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experiencing grade 3 toxicities. Nine (10%) patients, 4 with known EGFR or 
KRAS mutations, achieved RECIST partial responses. Median overall survival 
for patients enrolled versus not enrolled was 8.1 versus 3.7 months (p<0.001).  
Conclusions: 
Phase I trial therapies were generally well tolerated with potential antitumor 
benefit for patients with advanced NSCLC. Early referral to drug development 
units at time of disease progression should be considered to enhance the 
odds of patient participation in these studies.   
 
Key Words: NSCLC, phase I clinical trials, novel therapies 
 
Abbreviations: 
ALK: Anaplastic Lymphoma Kinase 
DDU: Drug Development Unit 
ECOG PS: Eastern Cooperative Oncology Group Performance Status 
EGFR: Epidermal growth factor receptor 
EPR: Electronic patient record 
HDAC: Histone deacetylase  
IGF-1R: Insulin growth factor-1 receptor 
LDH: Lactate dehydrogenase 
NSCLC: Non-small cell lung cancer 
OS: Overall survival  
PARP: Poly(ADP-ribose) polymerase inhibitor 
PI3K: Phosphatidylinositol-3 kinase 
PFS: Progression-free survival 
PR: Partial response 
RMH: Royal Marsden Hospital  
SD: Stable disease 
TKI: Tyrosine kinase inhibitor 
TTP: Time to progression 
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Highlights: 
1) Only 35% of patients referred to a dedicated Drug Development Unit 
commenced trial therapy, most commonly because of poor performance 
status and rapid disease progression. Early referral to dedicated phase I trial 
units should thus be considered to enhance the odds of patient suitability for 
such experimental studies. 
 
2) This study validated the Royal Marsden Hospital (RMH) prognostic score, a 
predictor of 90-day mortality, which comprises serum albumin levels, number 
of metastatic sites and lactate dehydrogenase (LDH) levels in patients with 
advanced NSCLC. 
 
3) Novel therapies assessed within phase I clinical trials were generally well 
tolerated in our series of patients with advanced NSCLC.  
 
4) Objective RECIST responses to rationally matched targeted therapies were 
observed in molecularly selected patients with advanced NSCLC harboring 
KRAS and EGFR mutations. 
 
5).  RECIST responses and TTP were comparable to those achieved with 
single agent chemotherapy regimens given in the relapsed setting for 
advanced NSCLC, e.g. docetaxel, and were associated with fewer treatment-
related adverse events. 
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1. INTRODUCTION 
Lung cancer is the main cause of cancer mortality worldwide and has a five-
year survival rate of less than 15%[1,2]. Non-small cell lung cancer (NSCLC) 
accounts for 85% of lung cancers and is histologically classified into 
adenocarcinoma and squamous cell carcinoma, which account for 50% and 
30% of NSCLC, respectively. NSCLC is a molecularly heterogeneous disease 
and may harbor different putative driver aberrations[3,4]. The landscape of 
therapeutic options for patients diagnosed with advanced NSCLC has 
changed dramatically over the past decade, especially with recent advances 
in the development of immunotherapies and next generation molecularly 
targeted agents[5-9]. Novel immune checkpoint inhibitors have demonstrated 
longer overall survival (OS) and better toxicity profiles compared to platinum-
based chemotherapy in patients whose tumors have ≥ 50% PD-L1 expression 
in the first-line setting, and to docetaxel in patients with advanced NSCLC 
who had progressed during or after platinum-based chemotherapy[5-7,10,11]. 
Phase III trials have demonstrated that first and second generation tyrosine 
kinase inhibitors (TKIs), such as erlotinib (Roche), gefitinib (AstraZeneca) and 
afatinib (Boehringer Ingelheim) in patients with epidermal growth factor 
receptor (EGFR) mutant NSCLC improve progression-free survival (PFS), but 
not OS when compared with platinum-based chemotherapy in the first and 
second-line settings[8,12-14]. Phase III studies performed in patients with 
Anaplastic Lymphoma Kinase (ALK) fusion rearrangements, which accounts 
for approximately 4% of NSCLC, when treated with crizotinib (Pfizer) have 
shown improvements in PFS compared with platinum chemotherapy[9,15]. 
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Despite advances in the development of antitumor therapies, there are still 
only a limited number of approved lines of treatment available for patients with 
advanced NSCLC. Patients are typically considered for clinical trials within 
specialist lung cancer units upon the exhaustion of conventional treatment 
options. Such trials are often limited by protocol restrictions on patient 
eligibility and number of prior lines of treatments received. Patients who 
remain fit with acceptable organ function may then be referred to specialist 
drug development units for consideration of phase I trials of novel 
experimental therapies, including first-in-human studies. However, to the best 
of our best knowledge, there are currently no published data on the outcomes 
of patients with advanced NSCLC treated within the context of phase I clinical 
trials in dedicated drug development units, including treatment-related 
toxicities and antitumor activity. Such data will be important to establish the 
extent of benefit which may be anticipated from experimental phase I trials are 
bona fide antitumor treatment options for patients with advanced NSCLC. 
 
A critical aspect of phase I trials is the selection of suitable patients, especially 
those with NSCLC who are at high risk of rapid clinical deterioration. Olmos 
and colleagues developed and validated the Royal Marsden Hospital (RMH) 
prognostic score - comprising serum albumin levels, number of metastatic 
sites and lactate dehydrogenase (LDH) levels - as a predictor of 90-day 
mortality to optimize the selection of appropriate patients for participation in 
phase I trials[16,17]. Such factors have not been assessed specifically in 
patients with advanced NSCLC.  
 
 7 
The main aim of this retrospective study was to evaluate the clinical outcomes 
of patients with advanced NSCLC referred to the Drug Development Phase I 
Unit at the Royal Marsden Hospital (RMH) for consideration of novel 
therapies, and to explore the outcomes of patients treated with molecularly 
targeted agents. The second aim was to identify baseline clinical factors 
associated with successful enrollment onto phase I clinical trials and validate 
the RMH prognostic score in patients with advanced NSCLC.  
 
2. MATERIAL AND METHODS 
This retrospective study included patients with advanced NSCLC who were 
referred to the Drug Development Unit (DDU) at the Royal Marsden Hospital 
(RMH), London, United Kingdom, for consideration of phase I clinical trials 
from 1st January 2005 to 31st December 2013. This study was approved by 
the Royal Marsden Hospital Committee for Clinical Research. 
 
Clinical parameters were collected from electronic patient records (EPR) 
during the patients’ first visit to the DDU prior to starting a clinical trial, 
including: stage of cancer, sites of disease, histological subtype, mutation 
status, prior lines of antitumor therapy, Eastern Cooperative Oncology Group 
performance status (ECOG PS), full blood count, biochemistry, RMH 
prognostic score and genetic mutation status if known. The RMH prognostic 
score, which comprise serum albumin, number of metastatic disease and 
lactate dehydrogenase (LDH) levels, is a predictor of 90-day mortality used to 
optimize the selection of patients for phase I clinical trials. All patients enrolled 
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on these clinical studies had provided their written informed consent for trial 
participation.   
 
The primary endpoint of this study was to evaluate patient outcomes 
(treatment-related toxicities and antitumor activity) of patients with NSCLC 
who enrolled in at least one phase I trial. Toxicity data were collected as 
originally reported on EPR, i.e. graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 3.0 or 4.0 depending on the 
study. Antitumor response rates were evaluated according to Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or 1.1 depending on 
the study. Tumor responses were confirmed by a board-certified radiologist. 
OS data were obtained from EPR and when necessary, by contacting the 
patients’ family physician. 
 
The SPSS program version 20 was used for the statistical analysis. Univariate 
and multivariate binary Cox logistic regression was used to identify clinical 
factors associated with patients being enrolled onto phase I trials. OS was 
defined as the interval between the day of the first administered dose of 
clinical trial therapy and the date of death from any cause. Time to 
progression (TTP) was the time elapsed between the first dose of trial therapy 
until radiological progression or death from any cause. The Kaplan-Meier 
method as used to estimate median TTP and OS. 
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3. RESULTS  
3.1 Patient and tumor characteristics 
A total of 257 patients diagnosed with advanced NSCLC were referred to the 
DDU at the RMH from January 2005 to December 2013 for consideration of 
participation in phase I clinical trials. Eighty-nine of these 257 (35%) patients 
participated in at least one phase I trial, with 17 of these 89 (19%) patients in 
two or more phase I trial (106 trial enrollments). A total of 168 of 257 (65%) 
patients referred to DDU did not start a phase I trial. Of these 168 patients, a 
total of 120 were deemed not suitable for allocation to a Phase I trial, while 48 
were allocated but did not start treatment (Figure 1). Overall, the main 
reasons for patients not participating in phase I clinical trials were poor ECOG 
PS (49 [29%]) and rapid disease progression (30 [18%]). Other reasons 
included patients not interested in participating in phase I clinical trials (22 
[13%]) and comorbidities such as cardiac disease and diabetes (16 [10%]). 
Details of other reasons are outline in Figure 1.   
 
Patient demographic characteristics were similar in the enrolled versus not 
enrolled groups, respectively: median age (61 vs. 60 years), histology (lung 
adenocarcinoma [63% vs. 66%] and squamous cell lung cancer [30% vs. 
27%]), ≥ 3 previous lines of antitumor treatment in the metastatic disease 
setting (42% vs. 46%), and prior use of molecular targeted agents (61% vs. 
58%), respectively. 95% of enrolled patients had an ECOG PS 0-1 versus 
69% in the non-enrolled group; RMH prognostic score 0-1 was 73% in the 
enrolled group compared with 45% in the non- enrolled group (Table 1). 
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Genetic aberration status (EGFR, KRAS and BRAF mutations; ALK 
rearrangements) was available for only 84 (33%) of 257 patients. 26 (31%) of 
these 84 patients referred for consideration of a phase I trial had a known 
KRAS mutation, while 8 (9%) had an EGFR mutation. Neither BRAF 
mutations nor ALK rearrangements were detected in our study (Table 1).  
 
3.2 Univariate and multivariate analysis 
Univariate and multivariate analyses were performed in order to investigate 
clinical factors associated with patients being enrolled versus not being 
enrolled onto phase I clinical trials. Clinical factors including the number of 
sites of disease (<3 sites), ECOG PS (0-1), RMH prognostic score (0-1), white 
blood cells (WBC) <109/L, neutrophils, lymphocytes, hemoglobin (>9g/dL), 
platelets (<400,000), albumin (>35g/L), alkaline phosphatase (<110) and LDH 
(<192 U/L) levels were significantly associated with being enrolled onto a 
phase I clinical trial in the univariate analysis (Table 2).  
 
However, the ECOG PS and RMH prognostic score were the only 
independent factors associated with successful patient enrollment using a 
multivariate analysis. Patient with ECOG PS 2-3 versus 0-1 (odds ratio (OR) 
0.06 [95% CI, 0-22-0.20; p<0.001]) and those with RMH prognostic score 2-3 
versus 0-1 (OR 0.29 [95% CI, 0.15-0.58; p<0.001]) were significantly less 
likely to be enrolled onto phase I trials. This validated the RMH prognostic 
score in patients with advanced NSCLC (Table 2). 
 
3.3 Phase I clinical trial therapies 
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We classified the individual drugs tested in the 26 phase I clinical trials into 
four categories: single agent targeted therapies (51 events [55%]), targeted 
therapy-chemotherapy combinations (18 events [19%]), targeted-targeted 
therapy combinations (14 events [15%]) and novel chemotherapies (10 events 
[11%]). Single agent targeted therapies included inhibitors against histone 
deacetylase (HDAC), the phosphatidylinositol-3 kinase (PI3K) pathway, 
insulin growth factor-1 receptor (IGF-1R), pan-HER family tyrosine kinase, 
antiangiogenic agents, poly(ADP-ribose) polymerase (PARP) inhibitors, 
integrins, aurora kinase inhibitors, PIM kinase inhibitors, monocarboxylase 
inhibitors and intravenous reovirus (Table 4). 
 
3.4 Phase I trial therapy-related toxicities 
We assessed the therapy-related adverse events collected during the duration 
of trial treatment of 106 patient enrollments. Overall, phase I trial therapies 
were well tolerated, with mainly grade 1- 2 adverse events. The most common 
toxicities at any grade included fatigue (33 patients [31%]), skin rash (31 
[29%]), diarrhea [27 (26%]) and nausea (26 [24%]). The most common grade 
3 or worse toxicities included diarrhea (6 patients [6%]), skin rash (5 [5%]), 
fatigue (5 [5%]) and acute allergic reactions (4 [4%]). The acute allergic 
reactions were observed in patients treated with chemotherapy and 
monoclonal antibodies. Grade 3 trial-related toxicities were observed in 25 
patients (24%), leading to 12 (11%) patients discontinuing trial therapy. No 
grade 4-5 toxicities were observed (Table 3).  
 
3.5 Antitumor activity 
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Of the 106 patient enrollments, 93 patients were evaluable for response 
assessment according to RECIST; the remaining 13 patients were not 
evaluable as they discontinued the trial early (11 because of toxicity and 2 
because of non drug-related reasons). Nine (10%) patients achieved a 
RECIST partial response (PR), 37 (40%) achieved clinical benefit (PR + 
stable disease [SD]) at 3 months and 15 (15%) at 6 months. Among the nine 
patients who achieved a RECIST PR, 8 patients had lung adenocarcinoma, 
while 1 had lung squamous cell carcinoma. All patients received at least 2 
prior lines of antitumor treatment in the metastatic setting and five out of nine 
patients had previously received a targeted therapy (Table 5).  
 
Median TTP for all novel therapies was 2.6 months (95% CI, 0.2-35.5). 
Patients who received a combination of drugs, especially targeted therapy-
chemotherapy combinations had the longest median TTP of 4.7 months (0.2-
35.5) and the highest rates of PR (Table 4). The median OS for the patients 
enrolled onto phase I trials versus not enrolled was 8.1 versus 3.7 months 
(HR 0.51 [95% CI; 0.40-0.67, p<0.0001]) (Figure 2). In addition, at 6 months 
after their first consultation in the Phase I DDU, 61% (95% CI, 51.11-71.89) of 
patients enrolled onto phase I trials were alive versus 36% (95% CI, 24.45-
39.35) patients who were not enrolled onto phase I trials (p=0.004). 
 
An actionable mutation was detected in four of 9 (44%) patients who achieved 
a PR on phase I trials; all four patients were treated with matched targeted 
therapies. Two never-smoker female patients with EGFR mutant NSCLC 
achieved a median TTP of 18 and 36 months with a single agent pan-HER 
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family tyrosine kinase inhibitor and a combination of paclitaxel chemotherapy 
and a pan-HER family tyrosine kinase inhibitor, respectively. Two ex-smoker 
patients with KRAS mutations had progressed on four lines of treatment, 
including platinum-doublet chemotherapy, docetaxel, pemetrexed and 
erlotinib. Both patients were treated with a combination of a selective MEK 
inhibitor and AKT inhibitor. One patient achieved a RECIST PR lasting four 
months and the other patient discontinued trial after 3.3 months because of 
non-trial related pneumonia; restaging imaging at the time of trial 
discontinuation showed RECIST PR (Table 5). 
 
4. DISCUSSION 
Treatment strategies for advanced NSCLC remain limited, thus novel 
experimental therapies within the context of early phase clinical trials may 
provide additional therapeutic approaches for these patients. In this study, we 
assess the outcomes of patients with advanced NSCLC treated on phase I 
trials within a dedicated drug development unit, including therapy-related 
toxicities and response rates. We also investigate clinical factors, which 
predict for successful enrollment onto phase I trials. In our retrospective study, 
novel therapies were generally well tolerated, with only 12 (11%) patients 
discontinuing trial because of adverse events. The rates of phase I trial-
related grade 3 toxicities of 24% were lower than the docetaxel-related grade 
3 toxicity rates of 40%-70%[18,19], but higher compared with grade 3-4 
toxicities reported in phase III studies with the immune checkpoint inhibitors 
nivolumab and pembrolizumab of 7%-10%[5,6,10]. 
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The identification of suitable patients for phase I trials remains challenging, 
especially in patients with advanced NSCLC who have a high risk of clinical 
deterioration. We therefore evaluated the RMH prognostic score -which 
comprises serum albumin level, number of metastatic sites and lactate 
dehydrogenase levels - and other potential clinical factors that may be 
associated with being enrolled onto phase I clinical trials. Our results were 
consistent with previous findings based on patients with advanced solid 
tumors and validated the RMH prognostic score, which is used as a predictor 
of 90 day-mortality, in patients with advanced NSCLC. The RMH prognostic 
score 0-1 and ECOG PS 0-1 were the only clinical factors found to be 
significantly associated with being successfully enrolled onto phase I trials in a 
multivariate analysis[16,17]. The ECOG PS and RMH prognostic score should 
therefore be used to identify suitable patients with NSCLC for phase I clinical 
trials. In addition, the early referral of patients with advanced NSCLC to 
dedicated phase I units should be considered so as to preserve both ECOG 
PS and RMH prognostic scores and to improve the odds of patients being 
successfully enrolled onto phase I studies. 
 
In our study, a large number of patients were heavily pretreated with 42% 
having had 3 or 4 prior lines of treatment in the metastatic setting. Overall, 
nine (10%) patients achieved RECIST PR, with median TTP of 2.6 months 
(95% CI, 0.2-35.5) and median OS of 8.1 months. These results are 
comparable with single agent chemotherapies, such as docetaxel and 
pemetrexed given in the second line treatment setting, which has a overall 
response rate of ≤10% and a TTP of 2-3 months[18,19]. The main limitation of 
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our study is that patients with advanced NSCLC were treated with different 
novel drugs or therapeutic combinations with different mechanisms of action. 
Some patients may also have been treated with subtherapeutic or ineffective 
drug doses during these phase I studies. This may explain the wide variability 
in the median TTP. 
 
Genetic aberration status (EGFR, KRAS and BRAF mutations; ALK 
rearrangements) was only available for only 84  (33%) of 257 patients. This 
may be explained by the fact that molecular characterization of patients with 
advanced NSCLC was not routinely tested during the early to middle parts of 
our study period between 2005-2013 and that very often, only limited amounts 
of tissue are available in diagnostic lung biopsies. National efforts such as the 
Cancer Research UK Stratified Medicine Program-2 are now ongoing to 
molecularly characterize patients with advanced NSCLC prospectively for 
enrollment onto the National Lung Matrix Trial20.  
 
In our study, 26 of 84 (31%) patients with available genetic aberrations were 
found to harbor a known KRAS mutation while 8 (9%) had an EGFR mutation, 
which are consistent with the proportion of KRAS and EGFR mutations 
described in the literature of 20%-30% and 10%, respectively[21]. It should be 
noted that 4 of nine patients who achieved confirmed PRs had known putative 
driver mutations, and were treated with matched molecularly targeted 
therapies. Two patients with known sensitizing EGFR mutations were treated 
with a pan-HER family tyrosine kinase inhibitor, achieving median TTPs of 18 
and 36 months. The patient in our study who achieved a median TTP of 36 
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months had a known deletion in chromosome 19 EGFR; according to the 
LUX3 and LUX6 studies, patients with del19 EGFR aberrations treated with 
afatinib had the longest OS lasting over 30 months[22].  
 
The other two patients who achieved RECIST PRs had known KRAS 
mutations and were treated with a combination of MEK and AKT inhibitors. 
Jänne and colleagues reported a randomized phase II study assessing the 
combination of docetaxel plus the MEK inhibitor selumetinib (AZD6244; 
AstraZeneca) versus docetaxel plus placebo in patients with KRAS mutant 
NSCLC in the second-line setting[23]. The selumetinib group showed a median 
PFS of 5.3 months (95% CI, 4.6-6.4) versus 2.1 months (95% CI, 1.4-3.7) in 
the placebo group (HR 0.58, p<0.014)[23]. Based on data from this phase II 
trial and our study, it appears that patients with KRAS mutant NSCLC may 
benefit more from the combination of a MEK inhibitor either with 
chemotherapy or a PI3K pathway inhibitor, than MEK inhibitor 
monotherapy[24]. The rationale for the latter combination strategy is because 
of the potential development of signaling crosstalk between the PI3K and the 
RAS/RAF/MEK pathways and subsequent drug resistance[25,26]. These early 
phase clinical trial findings suggest that such combination strategies are 
promising in KRAS mutant NSCLC where there are currently no approved 
targeted therapies. 
 
The management of patients with advanced NSCLC has changed 
dramatically in recent years, partly because of the development of novel 
immunotherapeutic approaches, including the FDA approval of novel immune 
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checkpoint inhibitors, such as nivolumab and pembrolizumab in patients with 
squamous and non-squamous NSCLC[5-7]. In addition, third generation EGFR 
mutation specific inhibitors, such as osimertinib are highly active in patients 
with EGFR T790M mutations who have progressed on first and second-
generation EGFR inhibitors[27,28]. Signals of antitumor activity in NSCLC in 
molecular subpopulations of patients with these agents were first observed in 
phase I trials, stressing the importance of such studies in accelerating drug 
development through the use of hypothesis-testing, biomarker-driven 
studies[29,30].  
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TABLES 
Table 1: Patients demographics 
Patient characteristics Patients 
enrolled 
n = 89 (35%) 
Patients not 
enrolled 
n = 168 (65%) 
All patients 
n = 257 
(100%) 
Age    
Median    
 < 65 years 60 (68%) 104 (62%) 164(64%) 
> 65 years 29 (32%) 64 (38%) 93 (36%) 
Sex  
Male 54 (61%) 88(52%) 142 (55%) 
Female 35 (39%) 80 (48%) 115 (45%) 
Race    
White 82 (92%) 150 (90%) 232 (91%) 
Asian 3 (3%) 11 (6%) 14 (5%) 
Black 4 (5%) 3 (2%) 4 (5%) 
Indian 0 (0%) 3 (2%) 3 (1%) 
Smoking status    
Ex-smoker 39 (44%) 86 (51%) 125 (49%) 
Smoker 11 (13%) 19 (11%) 30 (11%) 
Never smoker 23 (25 %) 18 (11%) 41 (16%) 
Unknown 16 (18%) 45 (27%) 61 (24%) 
Stage    
III 7 (8%) 7 (4%) 14 (5%) 
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IV 82 (92%) 161 (96%) 243 (95%) 
Histology    
Adenocarcinoma 56 (63%) 111 (66%) 167 (65%) 
Squamous 27 (30%) 45 (27%) 72 (28%) 
Other 6 (7%) 12 (7%) 18 (7%) 
Mutations    
Not available 63 (71%) 110 (65%) 173 (67%) 
Available 
- KRAS mutations 
- EGFR mutations 
26 (29%) 
8 (9%) 
3 (3%) 
58 (35%) 
18 (30%) 
5 (8%) 
 
84 (33%) 
26 (31%) 
8 (9%) 
Previous lines of 
treatment 
   
1 10 (11%) 18 (11%)  28 (11%) 
2 42 (47%) 67 (40%) 109 (42%) 
3 25 (28%) 57 (34%) 82 (32%) 
4 12 (14%) 21 (12%) 33 (13%) 
5 NA 5 (3%) 5 (2%) 
Chemotherapy first line 
doublet 
   
Platinum-based 
chemotherapy 
74 (83%) 152 (91%) 226 (88%) 
Other 3 (3%) 2 (1%) 5 (2%) 
First line single 12 (14%) 14 (8%) 26 (10%) 
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chemotherapy 
Erlotinib 52 (58%) 83 (49%) 135 (52%) 
Prior lines of targeted 
therapy 
54 (61%) 98 (58%) 152 (59%) 
ECOG PS    
0 16 (18%) 15 (9%) 31 (12%) 
1 69 (77%) 100 (60%) 169 (66%) 
2 4 (5%) 44 (26%) 48 (19%) 
3 NA 8  (5%) 8 (3%) 
RMH score    
0 19 (21%) 18 (11%) 37 (14%) 
1 46 (52%) 58 (34%) 104 (41%) 
2 17 (19%) 59 (35%) 76 (29%) 
3 7 (8%) 33 (20%) 40 (16%) 
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Table 2: Factor associated with enrollment onto phase I clinical trials. 
 Univariate analysis Multivariate analysis 
Variable OR 95% CI P value OR 95% CI P value 
Histology 
(Adenocarcinoma 
vs. others) 
0.98 0.55-
1.77 
0.967 NA NA NA 
Platinum sensitive 
vs. 
resistant/refractory 
0.66 0.35-
1.25 
0.213 NA NA NA 
Number of prior 
lines of treatment 
≥ 3 
0.71 0.40-
1.25 
0.240 NA NA NA 
Kras mutation 1.09 0.34-
3.45 
0.873 NA NA NA 
Number of sites of 
disease ≥ 3 
0.51 0.29-
0.92 
0.026 NA NA NA 
ECOG  (2-3 vs. 0-
1) 
0.05 0.20-
0.17 
0.001 0.06 0-22-
020 
0.001 
RMH prognostic 
score (2-3 vs. 0-
1) 
0.26 0.14-
0.48 
0.001 0.29 0.15-
0.58 
0.001 
WBC  > 109 / L 0.87 0.21-
0.73 
0.003 NA NA NA 
Neutrophils  0.87 0.80-
0.94 
0.001 NA NA NA 
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Lymphocytes 1.29 0.86-
1.92 
0.214 NA NA NA 
Hemoglobin > 9 
g/dL 
1.42 1.11-
1.71 
0.001 NA NA NA 
Platelets > 
400,000 
0.99 0.99-
1.00 
0.611 NA NA NA 
Albumin >35 g/L 3.39 1.73-
6.63 
0.001 NA NA NA 
Alkaline 
phosphate  > 110 
u/L 
0.26 0.12-
0.58 
0.001 NA NA NA 
LDH > 192 U/L 0.53 0.29-
0.97 
0.040 NA NA NA 
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Table 3: Main drug related toxicities according to CTCAE * 
Toxicities G1 (n, %) G2 (n, %) G3 (n, %) G4 (n, %) All grades 
Fatigue 14(13%) 14 (13%) 5 (5%) NA 33 (31%) 
Skin rash 12 (12%) 12 (13%) 5 (5%) NA 31 (29%) 
Diarrhea 13(12%)  8 (8%) 6 (6%) NA 27 (26%) 
Nausea 16 (15%) 10 (9%) NA NA 26 (24%) 
Mucositis 15 (15%) 6 (6%)  1 (1%) NA 22 (20%) 
Vomiting 9 (9%) 1 (1%) 1 (1%) NA 11 (10%) 
Allergic 
reactions 
NA 1 (1%) 4 (4%) NA 5 (5%) 
Liver 
transaminase 
elevation 
1 (1%) 1 (1%) 3 (3%) NA 5 (5%) 
Note: adverse events during the trial, i.e., exceeding dose-limiting toxicity 
period. 
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Table 4: Antitumor activity 
Novel therapies n (%) PR SD CB (PR 
+SD) for 
4 
months 
CB (PR 
+SD) 
for 6 
months 
Median 
TTP 
(months) 
(range) 
Single targeted therapies 
HDAC inhibitor 14 
(15%) 
NA 7 (50%)  2 (14%)  2 (14%) 2.4 (1.5-
3.5) 
PI3K pathway 
inhibitor 
9 
(10%) 
NA 4 (45%) 2 (22%) 2 (22%) 1.7 
(0.9-9.5) 
IGF-1R inhibitor 7 
(8%) 
NA 3 (37%) 1 (12%)  1.8 
 (0.7-
7.8) 
Virotherapy 4 
(4%) 
NA 3 (75%) 1 (25%)  2.5 
(1.8-4.8) 
Pan-HER family 
tyrosine kinase 
inhibitor 
    9 
(10%) 
2 
(18%) 
5 (46%) 3 (27%) 2 (18%) 3.5 
(0.6-
19.4) 
PARP inhibitor 1 
(1%) 
 1 
(100%) 
1 
(100%) 
 4.1 
Anti-angiogenic 
inhibitor 
1 
(1%) 
 1 (33%)   1.4 
Integrin inhibitor 1 
(1%) 
    1.4 
Aurora 1(1%)  1 1(100%)  5.8 
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Kinase inhibitor (100%) 
Monocarboxylate 
transporter 
inhibitor 
1(1%)      
2.6 
PIM kinase 
inhibitor 
1 
(1%) 
 1 (50%)   0.3 
c-MET inhibitor 1 
(1%) 
    0.9 
DNA 
methyltransferase 
1 
1 
(1%) 
    1.6 
Overall 51 
(55%) 
2 (4)  26 
(50%) 
11 
(22%) 
6 (12%) 3.2 
(2.4-4.3) 
Targeted therapy- chemo chemotherapy combinations  
 18 
(19%) 
4  10 
(55%) 
9 (50%) 6 (33%) 4.7 
(0.2-
35.5) 
Targeted-targeted therapy combinations 
 14 
(15%) 
3  7 (47%) 5 (33%) 2 (13%) 3.33 
(0.3-
14.0) 
Novel chemotherapies 
 10 
(11%) 
 5 (50%) 2 (18%) 1 (9%) 1.4 (0.6-
7.8) 
All drugs 
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 93 
(100%) 
9 
(10%) 
48 
(52%) 
27 
(29%) 
15 
(14%) 
2.6     
(0.2-
35.5) 
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Supplementary Table 1: Characteristics of the patients who achieved a PR 
Patient Age Se
x 
Histology Mutation ECOG 
PS 
Prior 
lines 
mtx  
Prior  
TT 
Type of drug TTP (months) 
1  73  F Adeno EGFR 0 2 No Paclitaxel + Pan-HER family 
tyrosine kinase inhibitor 
35.5 
2 45 F Adeno EGFR 2 2 Yes Pan-HER family tyrosine 
kinase inhibitor 
18.4 
3 * 62 M Adeno KRAS 0 4 Yes MEK inhibitor + AKT inhibitor 3.3 
4 62 F Adeno KRAS 2 4 No Mek-inhibitor + AKT inhibitor 4.2 
5 * 56 M Squamous No 2 2 No Paclitaxel + TORC1/2 
inhibitor 
4.7 
6 59 F Adeno No 0 2 No MEK inhibitor  + PI3K 
inhibitor 
14 
 28 
7 64 F Adeno Unknown  1 2 Yes Docetaxel + BCL2 inhibitor 6 
8 59 F Adeno Unknown 0 3 Yes Pan-HER family tyrosine 
kinase inhibitor 
11.2 
 9  68 M Adeno Unknown 1 2 Yes  Docetaxel + BCL2 inhibitor 7.5 
M: male; F: female; Adeno: adenocarcinoma; mtx: metastatic; TT: targeted therapy 
 
*Note: Patients 3 and 5 discontinued treatment because of non-disease related reasons (bilateral pneumonia and pneumothorax, 
respectively) 
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Figure 1: Flow chart of NSCLC patients participating in phase I clinical 
trial in the DDU at the RMH (2005-2013)  
257 patients with NSCLC 
were referred to the DDU 
for consideration of a 
phase I clinical trial 
(2005-2013) 
137 patients were 
allocated to ≥ 1 phase I 
clinical trial (152 
allocations, 17 patients 
allocated to ≥ 1 trial) 
89 patients participated in 
≥ 1 phase I clinical trial 
(106 allocations)  
 
120 patients were not  
suitable for allocation to 
phase I clinical trials 
48 patients were not 
suitable for participation 
in phase I clinical trials 
 
 
 
Reasons: 
49 (41%) ECOG PS 2-3 
22 (18%) not interested in phase I 
clinical trials 
16 (13%) comorbidities (diabetes, 
cardiac problems) 
15 (13%) availability of standard 
treatment options 
12 (10%) unstable brain 
metastases 
6 (5%) not disease progression 
 
 
 
 
Reasons: 
30 (63%) rapid progression of 
disease 
7 (15%)  availability of standard 
treatment options 
6 (12%) withdrawal of  informed  
consent for non-medical reasons 
5 (10%) trial screening failure due 
to inegibility 
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Figure 2: Overall survival of patients enrolled vs. not enrolled onto trial. 
 
 
 
  
8,1		vs.		3,7months	
HR:	0,51	(IC	95;	0.40-0.67;	
p-value	=	0,0001)	
Survival (months) 
Cumulative 
survival  
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